AU2022271791A1 — Combinations for treatment of cancer
Assigned to University of Texas System · Expires 2024-01-04 · 2y expired
What this patent protects
The present disclosure is directed to combinations of menin inhibitors and Bcl-2 inhibitors, optionally in further combination with hypomethylating agents and/or FLT3 inhibitors for the treatment of cancer. Specifically, menin inhibitors combined with venetoclax are synergistic i…
USPTO Abstract
The present disclosure is directed to combinations of menin inhibitors and Bcl-2 inhibitors, optionally in further combination with hypomethylating agents and/or FLT3 inhibitors for the treatment of cancer. Specifically, menin inhibitors combined with venetoclax are synergistic in the treatment of cancers with a HOX gene signature such as acute myeloid leukemia.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.